SEC Form 4 · accession 0001000229-17-000013
CORE LABORATORIES N V · CLB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark F Elvig
Officer — VP, Counsel & Secretary
Period of report
Dec 30, 2016
Accepted (ET)
Jan 4, 2017 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001000229
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Dec 30, 2016 | M | 2,200 | $0.00 | A | 21,527 | D | |
| Common Shares | Dec 30, 2016 | F | 602 | $120.04 | D | 20,925 | D | |
| Common Shares | holding | — | — | — | 2,568 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Performance SharesF1 | $0.00 | Dec 30, 2016 | M | 2,200 | D | — | — | Common Shares | 2,200 | 0 | D |
Explanation of responses
- F1The shares vesting were awarded as restricted performance shares in February 2014. As reported in the Form 4 filing on February 10, 2014 at the time the award was made, "The restricted performance shares will vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period and the shares shall fully vest if that criterion is met. If it is not met, then no shares shall vest and the award shall be forfeited." The performance criteria and all requirements for vesting have been met and thus the shares fully vested on December 30, 2016, at the conclusion of the performance period.